Palisade Bio announced new Phase 1a/b data for PALI-2108, an oral PDE4 inhibitor designed for targeted delivery to the colon and ileum in ulcerative colitis patients. The data show sustained active metabolite levels above the IC90 threshold, supporting once-daily dosing and localized drug activity in the colon, which reduces inflammation and fibrosis pathways. Clinical improvements were observed in biomarkers and histology, with 100% clinical response and 40% remission in patients. These results support advancing PALI-2108 into Phase 2 trials for ulcerative colitis and Crohn's disease.
Autonomize, a healthcare AI platform, has strengthened its leadership by appointing three industry veterans to its Advisory Board and hiring Mike Longacre as Head of Transformation. These moves aim to help healthcare organizations move beyond AI pilo...
Fairfax Financial Holdings has finalized its acquisition of Kennedy-Wilson Holdings at $10.90 per share in cash, led by a consortium including Kennedy Wilson's CEO William McMorrow and affiliates of Fairfax. The Kennedy Wilson management team retains...
Aya Gold & Silver Inc., a Canadian precious metals mining company operating in Morocco, will be added to the VanEck Gold Miners ETF (GDX) effective June 19, 2026. This inclusion marks a significant milestone reflecting the company's growth in product...
Nephros, Inc. emphasizes its ultrafiltration technology's ability to capture microplastics and nanoplastics in water, following the U.S. EPA's April 2026 decision to list microplastics as a priority contaminant under the Safe Drinking Water Act. The ...
After the US and Iran reached a deal expected to reopen the Strait of Hormuz, the world's largest tanker owner, Mitsui OSK Lines, cautions that shipping companies will wait for proof the agreement works before resuming normal traffic. The strait is c...
